Partner Therapeutics Initiates Patient Enrollment in U.S. Clinical Trial Evaluating Leukine® (rhuGM-CSF, sargramostim) in COVID-19 Patients
- Tuesday, August 25, 2020, 7:01
- Finance
- Add a comment
LEXINGTON, Mass., Aug. 25, 2020 /PRNewswire/ — Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced today that the first patient has been enrolled in the iLeukPulm clinical trial, a randomized phase 2 study of inhaled Leukine (sargramostim, rhu-GM-CSF) in…
About the Author
adminasapcorp has written 39694 stories on this site.